Clinical experience with aztreonam in four Mediterranean countries.
Aztreonam is a new, synthetic, monobactam beta-lactam antibiotic with activity directed specifically against aerobic gram-negative bacteria. At doses of 1-8 g per day, aztreonam was administered parenterally to patients with serious gram-negative infections of the urinary tract or other sites. A total of 462 organisms were isolated from sites of urinary tract infection; 93% of the isolates obtained within 48 hr before the initiation of aztreonam therapy were eradicated. Forty-three (86%) of 50 strains of Pseudomonas aeruginosa from urinary sites were eradicated. Eighty-six percent of gram-negative organisms isolated before treatment from other sites of infection were eradicated. Whatever the site of infection, the percentage of patients with a complete resolution of signs and symptoms was similar. Aztreonam was well tolerated both locally and systemically.
D000293:Adolescent; D000328:Adult; D001398:Aztreonam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002435:Cefamandole / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D004534:Egypt; D005060:Europe; D006088:Gram-Negative Aerobic Bacteria; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000209:etiology
D002435:Cefamandole; D001398:Aztreonam